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Background: In spite of radical gastrectomy with resection of the lymphatic system, where
no metastases are found during histopathological examination, about 30% of patients have
relapse of the neoplastic process. This situation may be caused by micrometastases or iso-
lated neoplastic cells in the lymphatic system which were not identiﬁed during a standard
histopathological examination.
Aim:The aimof the studywas to evaluate the clinical importance ofmicrometastaseswithin
the lymphatic system in patients with gastric cancer.
Materials and methods: A group of 20 patients treated for gastric cancer were subjected to
retrospective analysis. Of all thepatientswhounderwent surgery, a groupwith tumours clas-
siﬁed asT1 or T2was selected.Nometastaseswithin the lymphatic systemwere found in the
standard evaluation – N0mark. Parafﬁn-embedded blocks of lymph nodes were cut and new
specimens were made, which were then stained again by means of immunohistochemistry.
Antibodies against cytokeratin AE1/AE3 were used.
Results: A total of 319 lymph nodes were assessed in 20 patients in an H+E examination.
After the immunohistochemical examination, micrometastases within the lymphatic sys-
tem were found in 4 (20%) patients and isolated neoplastic cells in other 4 (20%) patients.Conclusion: On the basis of numerous publications and our own material, we think that the
presence of micrometastases may be related to a worse prognosis. The clinical importance
of micrometastases within the lymphatic system in patients after total gastrectomy.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
nostic factor is the state of the regional lymphatic system.1. Background
The incidence of gastric cancer in Europe and Poland shows a
falling tendency.Nevertheless, gastric cancer continues to be a
signiﬁcant clinical problem. It is the second malignancy caus-
ing most deaths around the world.1 The results of treatment
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of advanced gastric cancer are unsatisfactory and leave much
to be desired.
In patients with gastric cancer, the most important prog-Cancer Center, Garbary 15, 61-866 Poznan´, Poland.
In spite of radical gastrectomy with resection of the lym-
phatic system, where no metastases are found during a
histopathological examination, about 30% of patients have
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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elapse of the neoplastic process.2 This situation may be
aused by micrometastases or isolated neoplastic cells in the
ymphatic system, which were not identiﬁed during a stan-
ard histopathological examination. A standard procedure is
o subject a lymph node to section in one plane and to col-
ect two or three specimens, which are subsequently stained
ith haematoxylin and eosin. Small concentrations of gas-
ric cancer cells located in the subcapsular sinuses of lymph
odes may be overlooked during a standard histopatholog-
cal evaluation. The application of more sensitive methods
f histopathological evaluation such as immunohistochem-
cal examination or molecular biology techniques enables
dentiﬁcation of micrometastases and isolated tumour cells
ithin the lymphatic system, which were not found during a
tandard evaluation. Similarly, in the case of other tumours
uch as: breast cancer, melanoma, lung cancer or colorectal
ancer, the application of immunohistochemical staining for
valuation of the lymphatic system enables identiﬁcation of
icrometastases in up to 20–45% of patients on average.3–5
t present, there is no deﬁnite opinion concerning the impor-
ance of micrometastases within the lymphatic system.
. Aim
he aim of the study was to evaluate the clinical importance
f micrometastases within the lymphatic system in patients
ith gastric cancer.
. Material and methods
group of 20 patients treated for gastric cancer at the Depart-
ent I of General Surgery and Surgical Oncology, Greater
oland Cancer Centre, Poznan´, Poland, from 2002 to 2007 were
ubjected to a retrospective analysis. All consecutive, eligi-
le patients treated in this period were enrolled for the study.
o patient received neoadjuvant or adjuvant therapy. On the
asis of prior diagnosis of adenocarcinoma, all the patients
nderwent total gastrectomy with resection of the lymphatic
ystem, inclusive the second compartment (D2 resection). The
ontinuity of the alimentary tractwas reconstructed bymeans
f the Roux-Y method. After the surgery, all the patients
nderwent a standard histopathological evaluation of the
ntire resected specimen. The evaluationof the lymphatic sys-
em consisted in the section of the node and collection of one
r two specimens. After ﬁxing, the specimens were stained
ith haematoxylin and eosin and then subjected to micro-
copic assessment. Of all the patientswho underwent surgery,
group with tumours classiﬁed as T1 or T2 was selected. No
etastases within the lymphatic system were found in the
tandard evaluation – N0 mark. Parafﬁn-embedded blocks of
ymph nodes were excised and new specimens were made,
hich were then stained again by means of immunohisto-
hemistry. Antibodies against cytokeratin AE1/AE3 were used.
he obtained specimens were assessed by a histopathologist.
ccording to thedeﬁnition, the cellular depositswithdiameter
ange between 0.2 and 2mm were recognised as micrometas-
ases.On theotherhand, the concentrationsofneoplastic cellstherapy 1 6 ( 2 0 1 1 ) 232–236 233
with the diameter smaller than 0.2mm were recognised as
isolated tumour cells.
4. Results
A total of 319 lymph nodes were assessed in 20 patients in an
H+E examination, i.e. 15.96 nodes per patient, median 15.5.
After the immunohistochemical examination, micrometas-
tases within the lymphatic system were found in 4 (20%)
patients and isolated neoplastic cells in other 4 (20%) patients.
Thus, the application of the immunohistochemical exam-
ination enabled identiﬁcation of neoplastic cells within
the lymphatic system in 8 (40%) patients (Table 1). In all
the patients with diagnosed micrometastases, tumour was
located subcardially and the micrometastases were found in
the lymph nodes around the cardia, i.e. groups 1 and 2 in
the Japanese classiﬁcation. In two of the four patients apart
from the micrometastases there were isolated tumour cells
identiﬁed in another nodal station along the lesser curvature
station 3. The survival time of the patients with identiﬁed
micrometastases was lower than that of the patients with-
out neoplastic cells found within the lymphatic system after
immunohistochemical examination. It was 34.69 months vs.
49.86 months, respectively. In the case of isolated neoplas-
tic cells located in the lymphatic system, in comparison with
the N0 group after immunohistochemical examination, the
difference in survival time was 45.33 vs. 49.86, respectively.
On the other hand, in the group of patients with identi-
ﬁed micrometastases, the survival time was shorter in the
patients with isolated tumour cells identiﬁed in other nodal
stations besides the micrometastases, i.e. 16.15 months vs.
53.22 months. The statistical analysis was not performed due
to the group of patients being too small.
5. Discussion
Radical resection of the whole organ together with the lym-
phatic system still remains a standard method of treatment
of gastric cancer. Unfortunately, even as much as 13.8% of
patients who underwent radical resection due to early gas-
tric cancer inﬁltrating only the mucosa or submucosa have a
relapse of the neoplastic process. In a multi-factor analysis of
the causes of relapse of early gastric cancer, which comprised
a group of 3883 patients, Youn et al. recognised the following
negative risk factors: age, size of tumour, number of focuses
and state of lymph nodes. Of the elements listed above, it was
the state of the regional lymphatic system that proved to be
themost signiﬁcant factor of relapse. In the group subjected to
analysis, the most frequent occurrences were: the formation
of distant metastases (55.7%), local relapse (34%) and invasion
of the peritoneum (10.3%).6 Lai et al. presented similar con-
clusions on the basis of an analysis of 2923 patients with early
gastric cancer. The authors regarded the presence of metas-
tases in the lymphatic system to be the ﬁrst independent risk
factor of relapse of the neoplastic process.7 It is very likely
that relapse of the neoplastic process is caused by unidenti-
ﬁed micrometastases of the gastric cancer which are present
in the lymphatic system.
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Table 1 – Patients with micrometastases (MM) and isolated tumour cells (ITC).
Age Sex T Grade Lauren Number of examined
lymph nodes
IMH Site of MM/ITC
1 72 Male T2a G2 Intestinal 11 MM/ITC 1,2/3
2 53 Male T1b G3 Mixed 20 MM 1,2
3 65 Male T2a G1 Intestinal 26 ITC 1,2
4 74 Male T2a G2 Intestinal 30 ITC 4
5 72 Male T2a G3 Intestinal 14 MM/ITC 1,2/3
6 80 Male T2a G2 Mixed 24 MM 1,2
7 80 Female T2a G2 Mixed 12 ITC 3
solate8 50 Male T1a G3 Mixed
IMH – immunohistochemical staging; MM – micrometastases; ITC – I
The introduction of new methods of histopathological
assessment, such as immunohistochemistry or molecular
biology techniques, enableddetection ofmicrometastases and
isolated tumour cells of gastric cancer within the lymphatic
system. In the available literature,micrometastaseswithin the
lymphatic systemwere identiﬁed in a group of 10%up to 68.1%
of patients with diagnosed gastric cancer, regardless of the
degree of progression.8–12 In early gastric cancer, the frequency
of occurrence of micrometastases ranges between 10% and
25%. In our research, the presence of micrometastases within
the lymphatic system was diagnosed in 20% of the patients
with T1 and T2 tumours. Cao et al. present similar results in
a studied group of patients with gastric cancer after immuno-
histochemical examination of specimens of lymph nodes
with cytokeratin AE1/AE3. The presence of micrometastases
was diagnosed in a group of 21.3% of patients.13 Lee reports
that the application of immunohistochemical examination
increased the percentage of identiﬁedmetastatic lymphnodes
from 13% to 34%.10 In all of the presented publications, the
evaluation of the lymphatic system was made by means of
immunohistochemical examination with the application of
AE1/AE3 antibodies against cytokeratin.8,13–15 Identiﬁcation
of micrometastases in the lymphatic system is also possible
when molecular biology techniques are applied. The applica-
tion of the technique of reverse transcriptase in a polymerase
chain reaction with the use of cytokeratin 20 gene as a marker
also enabled identiﬁcation of micrometastases in a 46.7% of
patients after resection of gastric cancer. According to Mat-
sumoto et al., the application of RT-PCR is a more sensitive
examination than immunohistochemical staining, 28% vs.
14% in identiﬁcation of micrometastases in patients with gas-
tric cancer.8 However, as Yamamoto suggests, the application
Table 2 – Clinical impact of micrometastases found in lymph no
Author Year Method Antib
Siewert 1996 IMH AE1/AE
Ishida 1997 IMH CEA, CA
Fukagawa 2001 IMH AE1/AE
Nakajo 2001 IMH AE1/AE
Lee 2002 IMH AE1/AE
Ishigami 2003 IMH AE1/AE
Doekhie 2005 IMH CAM 5.2
Wu 2007 RT-PCR CK-20
Cao 2010 IMH AE1/AE
IMH – immunohistochemical staging; RT-PCR – reverse transcription polym14 ITC 1,2
d tumour cells.
of RT-PCR may detect not only the cells of gastric cancer but
also theDNAof the tumour, simultaneously resulting in a high
percentage of falsely positive results.16
The clinical importance of micrometastases and their
inﬂuence on patients’ survival rate continues to raise argu-
ments and controversies (Table 2). Both the reports by Ishii and
Lee show that the group of patients with micrometastases in
the lymphatic system had aworse prognosis than an identical
group without micrometastases. The differences in the 5-year
survival rate were statistically signiﬁcant and they reached
49% for the group with micrometastases, whereas for the
group without micrometastases they amounted to 76%.14,17
In another publication by Ze-Yu Wu, a group of patients with
micrometastases had a shorter mean survival rate– (18±7.4
months) in comparison with the group without micrometas-
tases (22.86±3.17 months). The difference was statistically
signiﬁcant p<0.05. The authors present similar results for
cancers of the cardia and distal part of the oesophagus, where
the presence of micrometastases was a signiﬁcant factor of
local relapse and dissemination of the neoplastic process.18
Cao et al. showed in their latest publication that in comparison
with patients without micrometastases patients’ survival rate
was longer and statistically signiﬁcant (p<0.001), regardless
of the single-cell or clustered-cell type of micrometastasis.13
Fukagawa et al. present different results. They did not observe
statistical signiﬁcance in a 5-year and 10-year period of obser-
vation of patients with identiﬁed isolated neoplastic cells in
the lymphatic system, as compared with a group of patients
without isolated neoplastic cells. The differences were 94%
vs. 79% and 89% vs. 74% (p>0.05), respectively.15 Fukagawa’s
publication was based on an analysis of the results of patients
treated in two centres, American and Japanese. The study
des of patients with gastric cancer.
ody Upstaging Impact on prognosis
3 90% Negative
M 5.2 17.6% Negative
3 36% None
3 15% Negative
3 24% Negative
3 9% Negative
49% Negative
46.7% Negative
3 21.3% Negative
er chain reaction.
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oncerned only isolated neoplastic cells. In the authors’ opin-
on isolated neoplastic cells do not exhibit a tendency tomake
etastases by proliferation, they do not react with the stroma,
o not inﬁltrate the vessels or structures of lymph nodes. This
ight explain why such a small amount of metastasis in the
ymph node is not a risk factor of relapse andworse prognosis.
n our material, the biggest difference in patients’ survival
ime was observed in the patients who had micrometastases
ithin the nodal station nearest the tumour and isolated
eoplastic cells in other stations in comparison with the
roup without any metastases. On average, the patients with
nvaded lymphatic systems survived 16.15 months, whereas
hose without metastases survived 40.75 months.
In the process of metastatic formation in the lymphatic
ystem, tumourous cells migrate via the lymph vessels to the
ymph nodes, where the following stages of settlement, inva-
ion and proliferation occur. However, individual tumourous
ells are detected by means of immunohistochemical exami-
ations or molecular biology techniques. They are eliminated
n the lymph nodes by the immune system in the process of
rreversible cell cycle arrest or induced apoptosis. According
o the theory of cancer stem cells, gastric cancer progeni-
or cells must be present within the lymph node to form a
etastasis in that place.19 The absence of progenitor cells in
he lymph node may account for the observation by Nakajo
t al. and Siewert et al., who found that isolated neoplastic
ells did not exhibit proliferative activity and did not inﬁltrate
he node structure.20,21 Individual non-progenitor tumourous
ells found in the lymph node should not have clinical sig-
iﬁcance. In the case of micrometastases, which according
o the deﬁnition have a diameter of more than 0.2mm in
ight microscopy, they are more likely to contain progenitor
ells. This would account for worse prognosis and shorter
urvival rate of this group of patients in comparison with
atientswithoutmetastases in the lymphnodes. Thedetermi-
ation of clinical importance ofmicrometastases and isolated
eoplastic cells may contribute to a better knowledge of the
echanisms of relapse of the neoplastic disease. Recently,
ew drugs have appeared, e.g. lapatinib, which is used in the
djuvant therapy of patients with gastric cancer. In combi-
ation with standard chemotherapy, these drugs signiﬁcantly
ncrease the 5-year survival rate. It is necessary to precisely
pecify the indications for this type of therapy. The application
f chemotherapy, radiotherapy as an adjuvant therapy (and
mmunotherapy in the future) may be of utmost signiﬁcance,
specially in patients with minimal deposits of neoplastic
ells.22–24
. Conclusion
he introduction of new methods of assessment of the lym-
hatic system resulted inmore detections ofmicrometastases
nd isolated neoplastic cells. At present, there is no ﬁnal con-
ensus concerning their clinical importance. However, on the
asis of numerous publications and our own material, we
hink that their presence may be related to a worse prognosis.
hey are an important factor of relapse of the neoplastic pro-
ess. They may play a crucial role in the process of qualifyingtherapy 1 6 ( 2 0 1 1 ) 232–236 235
for adjuvant chemotherapy, which offers a chance to improve
the effects of treatment.
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